The majority of pharmacogenetic studies have focused on the mechanism of action of CsA, with the first work reporting a significant association between the rare ABCB1 rs1045642 allele and negative CsA response in 84 psoriasis patients [56]. The gene discussed is ABCB1; the disease is psoriasis.